Dianthus Therapeutics Inc. (DNTH)vsRevolution Medicines Inc (RVMD)
DNTH
Dianthus Therapeutics Inc.
$88.55
-2.38%
HEALTHCARE · Cap: $5.50B
RVMD
Revolution Medicines Inc
$204.97
+2.56%
HEALTHCARE · Cap: $41.32B
Smart Verdict
WallStSmart Research — data-driven comparison
Dianthus Therapeutics Inc. generates 157% more annual revenue ($1.90M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. DNTH earns a higher WallStSmart Score of 34/100 (F).
DNTH
Avoid34
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 294.3% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
ROE of -22.7% — below average capital efficiency
Trading at 16.9x book value
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : DNTH
The strongest argument for DNTH centers on Revenue Growth, Debt/Equity, Altman Z-Score. Revenue growth of 294.3% demonstrates continued momentum.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : DNTH
The primary concerns for DNTH are EPS Growth, Profit Margin, Piotroski F-Score.
Bear Case : RVMD
The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.
Key Dynamics to Monitor
DNTH profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.
RVMD carries more volatility with a beta of 1.41 — expect wider price swings.
DNTH is growing revenue faster at 294.3% — sustainability is the question.
DNTH generates stronger free cash flow (-49M), providing more financial flexibility.
Bottom Line
DNTH scores higher overall (34/100 vs 24/100) and 294.3% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Dianthus Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. The company is headquartered in New York, New York.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?